KRISTINA BARBERA: Open Payments
NPI 1972152353 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,051 in 54 payments from 18 companies in 2025. Trend: 2023 $726 · 2024 $1,370 · 2025 $1,051
Food & beverage: $1,051
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $191 |
| Novo Nordisk Inc | 6 | $124 |
| AstraZeneca Pharmaceuticals LP | 5 | $102 |
| PFIZER INC. | 4 | $88 |
| GlaxoSmithKline, LLC. | 4 | $78 |
| Lilly USA, LLC | 4 | $75 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Astellas Pharma US Inc | 2 | $52 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| Exact Sciences Corporation | 2 | $46 |
Products named: UBRELVY, Ozempic, Wegovy, QULIPTA, VRAYLAR, MOUNJARO, TRELEGY ELLIPTA, NURTEC ODT.
Industry payments across DC — which companies pay providers there.
